Accueil
Envoyer à un ami
Imprimer
Grand
Petit
Partager
ACTUALITES

Boehringer Ingelheim welcomes central role of LAMA/LABA therapy within 2017 GOLD Strategy for COPD


- 16 Novembre 2016 modifié le 1 Janvier 1970


• Pharmacologic treatment recommendations are tailored to patients' needs based on symptoms and exacerbation history1

• LAMA/LABA therapy now an essential cornerstone for COPD treatment across the spectrum of people with COPD in GOLD groups B-D1

• Clearer guidance for physicians on which subset of patients may benefit from the addition of ICS1

(BUSINESS WIRE)-- Boehringer Ingelheim welcomes the updated 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy which now positions a combination of a LAMA (long-acting anticholinergic) and a LABA (long-acting beta2-agonist), as a mainstay treatment for people with Chronic Obstructive Pulmonary Disease (COPD) in GOLD groups B-D. ...

Source : http://me-newswire.net//news/19077/en...




Dans la même rubrique :
< >

Vendredi 2 Décembre 2016 - 17:42 Yahya-Hollande

ACTUALITES | INTERNATIONAL | TCHAD | POLITIQUE | CULTURE | EXCLUSIF | Revue de Presse | English News | 中國